Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07607938 · ClinicalTrials.gov registry record · Phase 1
Psilocybin as a Novel Therapy for Residual Anhedonia
A Phase 1 study, sponsored by NYU Langone Health.
- Not yet
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT07607938 is a Phase 1 study that has not yet begun recruiting, run by NYU Langone Health. The registered enrollment target is 90 participants.
The verdict
NCT07607938, a Phase 1 study, has not yet begun recruiting, sponsored by NYU Langone Health.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
The primary objective is to evaluate whether a single dose of psilocybin (25 mg), compared to placebo, can restore fronto-striatal reward circuit function and thereby improve anhedonia and emotional blunting in individuals with residual symptoms despite ongoing SSRI or SNRI treatment. This will be assessed using precision functional mapping (PFM), task-based fMRI, and clinical rating scales (DARS).
Interventions
- DRUG Placebo
- DRUG Psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-07 |
| Est. Completion | 2030-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07607938
The ClinicalTrials.gov registry entry for NCT07607938 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07607938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07607938 about?
NCT07607938 is a clinical study titled "Psilocybin as a Novel Therapy for Residual Anhedonia". The primary objective is to evaluate whether a single dose of psilocybin (25 mg), compared to placebo, can restore fronto-striatal reward circuit function and thereby improve anhedonia and emotional blunting in individuals with residual symptoms despite ongoing SSRI or SNRI treatment. This will be a...
What is the current status of trial NCT07607938?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2026-07. Estimated completion is 2030-09-30.
What interventions are being tested in trial NCT07607938?
The interventions under investigation include: Placebo (DRUG), Psilocybin (DRUG).
Who is sponsoring clinical trial NCT07607938?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.